Patent ID: 6949522

Claim:
A method for the treatment of an HIV infection in a host, comprising administering an effective treatment amount of a β-D or β-L-3′-halonucleoside of the formula (II): or its pharmaceutically acceptable salt, optionally in combination with a pharmaceutically acceptable carrier, wherein X is S; Y is fluoro, chloro, bromo or iodo; R 1 is hydrogen, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, aryl, alkylsufonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di or triphosphate or a phosphate derivative; Y 1 is OH, OR 2 , NH 2 , NHR 2 , NR 2 R 3 , SH, SR 2 or halogen; X 1 and X 2 are independently selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, halogen, OH, OR 4 , NH 2 , NHR 2 , NR 4 R 5 , SH or SR 4 ; and R 2 , R 3 , R 4 and R 5 are independently H, straight chained, branched or cyclic alkyl, dialkylaminoalkylene, dimethylaminomethylene), CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate.